A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
Latest Information Update: 12 Feb 2026
At a glance
- Drugs HRS 7085 (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 06 Feb 2026 Planned number of patients changed from 30 to 66.
- 06 Feb 2026 Planned End Date changed from 1 Mar 2026 to 1 Dec 2026.
- 06 Feb 2026 Planned primary completion date changed from 1 Mar 2026 to 1 Dec 2026.